Wealth Engine Pro
Insights
Market Analysis, Financial Commentary & Opinion
Data-driven perspectives on the markets, corporate finance, and investing from the team behind Wealth Engine Pro.
89 articles
Battle Stocks: Netflix vs. Disney
Netflix and Disney both broke in 2026. One is down 42 percent from its high and still trades 58 percent above fair value. A head-to-head before Netflix reports Thursday, and the data picks the other one.
The BYD Playbook Comes for Space
China caught an orbital booster on Friday. SpaceX trades near 100 times sales. The industrial pattern that built BYD, CATL, and Chinese solar is now aimed at launch, and the market is not pricing the erosion schedule.
The Five: The Earnings Season Watchlist
Q2 earnings season opens with a 23.9% growth bar. Five reports in the next four weeks where the platform scores and the market price disagree most: BAC, NFLX, TSLA, INTC, PYPL. Each print settles something.
Cloudflare: A Great Network at an Impossible Price
Cloudflare rallied to a record the same week the AI trade cracked. It trades at 27 times sales and 56 times book, is not yet profitable, and its insiders have sold $160 million into the rally.
Hormuz Watch: The Trigger Fired
Two weeks after we closed the weekly watch on the data, the June detente is coming apart. Missiles hit tankers in the Strait, the US and Iran are trading strikes, and Brent is back near $78. The implementation watch is live again.
Read articleThe Case for Globus Medical: The #2 Spine Company Hits Its Stride
An investment thesis for Globus Medical (GMED). The second-largest company in global spine, growing revenue 27% and earnings 65% last quarter while expanding margins, trades near 17 times forward earnings and about 29% below the platform fair value. A growth-at-a-reasonable-price case, with the integration and moat risks treated honestly.
Battle Stocks: Delta vs. United vs. Southwest
Fares up 20 percent, fuel falling, and Delta reports Friday. A head-to-head breakdown of DAL, UAL, and LUV, where the platform scores say the market is celebrating the wrong airline.
The Five: The Mid-Year Reset
Five Elite and Strong rated companies that fell in the first half of 2026 while their fundamentals held: RMD, TW, KNSL, DECK, CPRT. The platform scores, what knocked each one down, and what the data says now.
Nebius: Priced for 2028, Financed Until Then
Nebius reported a $621 million profit and $2.3 billion in operating cash flow. Both came from one-time items, while a $25 billion buildout runs on borrowed money.
The AI Trade Just Became a Credit Trade
For two years the AI buildout was funded by cash flow, so a stumble only dented earnings. That flipped. Hyperscalers are now borrowing toward $1.5 trillion, and the risk has quietly migrated from equity holders to the bond market.
Read articleThe Case for Cirrus Logic: An Elite Chipmaker Quietly Diversifying Beyond Apple
An investment thesis for Cirrus Logic (CRUS). The highest-strength name on the platform: an Elite-rated, debt-free chipmaker inside nearly every iPhone, with a record fiscal 2026 and a credible plan to diversify beyond Apple. A quality-and-catalyst case, with the concentration risk treated honestly.
Battle Stocks: Procter & Gamble vs. Unilever vs. Colgate-Palmolive
Three consumer staples giants head to head: P&G, the premium compounder; Unilever, the cheap turnaround; Colgate, a dominant moat with a balance-sheet problem. The data picks a winner.
The Five: Geared to Gold
Five Strong, undervalued gold miners offering leverage to a record gold price: NEM, AEM, KGC, IAG, SSRM. The platform scores, the operational leverage, and the one risk that matters most.
Hormuz Watch: Week 17: The Crisis That Repriced the World
The final weekly entry. Sixteen weeks ago a closed strait sent oil above $126 and repriced the global economy. This week, with a deal signed and Brent back below $74, the acute crisis is over. The scorecard: what it cost, how it ended, and what is left to watch.
Read articleRon Baron's $14 Trillion Bet on Starlink, Tested Against the Data
Ron Baron says Starlink will reach 300 million subscribers, $1 trillion in revenue, and a $14 trillion valuation in a decade. That needs a 30x jump in users and a tripling of ARPU at once, while ARPU is falling. The arithmetic, tested.
Affirm: A Lender Priced for Perfect Weather
Affirm just hit GAAP profitability with record volume and the lowest delinquencies of the cycle. At nearly 50 times forward earnings, the valuation assumes none of it ever reverses.
Why Be a Gambler When You Can Become the Casino
Most people trade options like gamblers buying lottery tickets. The durable money is on the other side of the table, selling them. What Buffett, three decades of index data, and a few spectacular blow-ups reveal about income from selling options.
Read articleThe Case for Kinsale: The Best Underwriter in Insurance Goes on Sale
An investment thesis for Kinsale Capital (KNSL). One of the most profitable underwriters in insurance, with a 77.4% combined ratio and a 24% return on equity, trading near a 52-week low at about 13 times earnings after a growth slowdown the market may have overrated.
Battle Stocks: JPMorgan vs Goldman Sachs vs Morgan Stanley
Three Wall Street giants posted record or near-record quarters on the 2026 capital-markets boom, yet the platform splits them sharply. A Battle Stocks comparison of JPM, GS, and MS. The data picks JPMorgan, and flags Goldman as the cyclical caution.
The Five: Built for Higher Rates
The Fed just took rate cuts off the table. Most stocks fight higher-for-longer; these five earn more when rates stay high, through net interest income, insurance float, and the spread on idle client cash.
Hormuz Watch: Week 16: The War Ends, the Bill Stays
The US and Iran signed a deal at Versailles to end the war and reopen the Strait of Hormuz. Oil fell to a three-month low and gas dropped below $4. The same afternoon, the Fed erased its 2026 rate cut and penciled in a hike. The shooting stops. The paying begins.
Read articleHims & Hers: The Growth Stopped, the Multiple Did Not
Hims & Hers grew revenue just 4% last quarter, compressed gross margin from 73% to 65%, and swung to a $92 million net loss. The stock rallied 45% anyway, on a peptide market the FDA has not approved.
The Fed Is About to Stop Telling You What It Thinks
Everyone is watching whether the Fed cuts. That is the wrong thing to watch. The real event of Kevin Warsh’s first meeting is whether the Fed stops telling markets what it thinks at all.
Read articleThe Case for Barrick: A Gold Major Priced Like the Rally Ends Tomorrow
An investment thesis for Barrick Mining (B). A gold major generating record free cash flow, trading near twelve times earnings with a fresh $3 billion buyback and a North American spinoff catalyst, while the market still prices miners for a gold-price reversal.